HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

iCpG-ODN

toll-like receptor 9 (TLR9) antagonist; has anti-inflammatory activity in response to cerebral ischemia or reperfusion injury in mice

Also Known As:

ODN2088

Networked: 10 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Oligodeoxyribonucleotides: 2217
        iCpG-ODN: 10

Experts

1.	Alzahrani, Badr: 2 articles (03/2022 - 01/2021)
2.	Ha, Tuanzhu: 2 articles (05/2013 - 01/2013)
3.	Kalbfleisch, John: 2 articles (05/2013 - 01/2013)
4.	Li, Chuanfu: 2 articles (05/2013 - 01/2013)
5.	Liu, Li: 2 articles (05/2013 - 01/2013)
6.	Wang, Xiaohui: 2 articles (05/2013 - 01/2013)
7.	Williams, David: 2 articles (05/2013 - 01/2013)
8.	Elshafae, Said M: 1 article (03/2022)
9.	Gaballa, Mohamed M S: 1 article (03/2022)
10.	Moussa, Maha A: 1 article (03/2022)

Related Diseases

1.	Stroke (Strokes) 01/01/2017 - "iCpG-ODN did not alter the levels of TNF-α or INF-β in the peripheral blood or affect stroke-induced changes in the number of splenocytes. " 01/01/2017 - "These findings suggest that iCpG-ODN induced protection against cerebral I/R via inhibiting inflammatory responses in a dose-dependent manner and may be useful in therapy for stroke patients."
2.	Pulmonary Fibrosis (Fibrosing Alveolitis) 03/01/2022 - "A marked decrease in pulmonary epithelial and endothelial apoptosis rate as measured by cleaved caspase-3 expression, inflammatory reaction as indicated by tumor necrosis factor α expression, and pulmonary fibrosis as demonstrated by Van Gieson staining and α-smooth muscle actin immunohistochemistry were observed following ODN2088 treatment. "
3.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2017 - "This study examined the effect of different dosages of the TLR9 antagonist inhibitory oligodeoxynucleotide (iCpG-ODN) on cerebral I/R injury by using a mouse model of transient middle cerebral artery occlusion. "
4.	Reperfusion Injury 01/01/2017 - "The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice." 01/01/2020 - "Mice were subjected to sham surgery or 30 minutes renal ischemia and reperfusion injury after receiving mesoscale nanoparticles encapsulated with a selective TLR9 antagonist (unmethylated CpG oligonucleotide ODN2088) or mesoscale nanoparticles encapsulating a negative control oligonucleotide. "
5.	Lung Injury 06/01/2017 - "In vivo, the lung injury score, the TLR9, MyD88, p-IRAK4 and p-p65 protein levels, and cytokines TNF-α and IL-1β levels in paraquat group were significantly higher than that in the control group;TLR9 blocker ODN2088 pretreatment attenuated lung injury, inhibited MyD88 and NF-κB activation, and reduced TNF-α and IL-1β in serum. "

Related Drugs and Biologics

1.	Caspase 3 (Caspase-3)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Oligodeoxyribonucleotides
4.	CPG-oligonucleotide
5.	Cytokines
6.	Toll-Like Receptor 9
7.	Proteins (Proteins, Gene)
8.	Paraquat
9.	Oligonucleotides
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Punctures
3.	Ligation